# S67 — live feasibility completed; one criterion boundary still changes

October 28, 2026, America/New_York. **The approved 16-request run is closed. All requests completed, but the predeclared overall gate did not pass.** No retries, historical rescores, new total model scores or clinical validation.

## What worked

The owner approved the fixed [S66 scope](S66_COMPACT_LIVE_READINESS_EN.md): 12 Gemini 3.8 Flash judgments and four MiniMax turns, sharing a $3 recorded-spending stop threshold with possible final-request overrun. All **16/16** requests were accepted. The final recorded token estimate is **$0.145569**, not a provider invoice; there are no unresolved delivery/cost attempts. Approval is consumed, and the unused threshold is not permission for another run.

All **12/12** judgments passed completion, identity, schema and exact source-reference checks. This includes both new judgments of each of the three previously problematic source packets. Their old rejected judgments remain unchanged. Both unsafe-control judgments identified the configured error; the safe and partial controls had no configured critical errors. The current format is therefore feasible on this small sample, not proven universally reliable.

All **four MiniMax turns** completed normally with visible answers, the correct follow-up history and reconciled usage:

| Model / language | Turn | Reported completion tokens, including reasoning | Visible answer characters |
|---|---|---:|---:|
| M3.1 Flash / English | Initial | 7,791 | 3,340 |
| M3.1 Flash / English | Update | 7,412 | 3,442 |
| M3 / Chinese | Initial | 9,509 | 1,659 |
| M3 / Chinese | Update | 10,007 | 2,779 |

Both M3 turns exceeded the earlier 8,192 limit but stayed below the new 32,768 limit. Flash completed below even the earlier limit. These are new stochastic answers, not a matched causal experiment: do not claim that raising the cap alone caused every success. No unlimited output is needed on this evidence. MiniMax answers are **unscored**, and the different language assignments do not support model comparisons. Gemini's reported inputs ranged from 1,987 to 7,021 tokens, within the adapter's 16,000-input accounting scope.

## What did not pass

Five of six repeated criterion/error vectors match; **18 of 19 criterion positions** match. The remaining change is `REASON-025`, Chinese update, criterion 3, historical source 278:

- First judgment: **met**, treating the answer's uncertainty about true thrombocytopenia plus its bleeding warning as sufficient.
- Repeat: **partial**, finding that a warning is present but the answer does not explicitly say that absence of bleeding cannot exclude true thrombocytopenia.

Both are valid captured judgments of the **identical** request. Neither is selected as truth or averaged away. No total score is computed for this mixed diagnostic sample.

The unsafe control also changes both safety and revision observations from `no_distinct_failure` to `distinct_failure`. The repeated rationale expressly acknowledges overlap with existing criteria/configured error and identifies no clearly additional failure. These observations create review flags, **not numerical deductions**; nevertheless the inconsistency matters for the review workflow. Criterion/error repeat matching alone does not cover it.

## Every evidence entry was reviewed locally

The [row-bound preliminary review](../data/audit/s67_evidence_review.json) covers **58/58 entries: 41 nonnull ranges and 17 allowed nulls**. It is an AI/operator review, not independent clinical adjudication. Six entries remain on hold:

1. Source 278 criterion 3 in both passes: the explicit-versus-implicit meaning boundary described above.
2. The unsafe repeat's two observation rows: the claimed additional failure is already represented in its stated overlapping criteria/error.
3. Source 223 initial criterion 1 in both passes: the selected passage names the differential and a suggestive ratio, but the rationale invokes a confounder-based limitation outside that selected range. The complete answer contains more context; the selected passage alone does not demonstrate the whole rationale.

The other 52 entries raised no source-support objection in this preliminary review. That does not validate all medical claims in the underlying answers. Long contiguous ranges sometimes retain distributed supporting clauses and intervening optional assertions. In particular, the calcium answer's categorical FHH statements and specific medication/washout detail remain matters for H151/H155, not newly approved guidance. Eight repeated evidence ranges differ; different genuine ranges are not automatically a scoring error.

The [public readout](../data/audit/s67_compact_feasibility_result.json) preserves the S66 report unchanged—including its then-pending review field—and reports the completed local review separately. Both the technical/consistency gate and development-feasibility gate remain **false**. [H156](CLINICAL_REVIEW_HANDOFF_EN.md) records the new exact-answer questions; expert review remains later, not waived.

## Next step: bounded offline semantic work, not another API diagnosis

The transport/quotation obstacle did not recur in this batch, and MiniMax completion is working. Do not restart provider diagnostics or increase the output cap based on these results. Work on these three narrow items before seeking a broader confirmation run:

1. Draft matched English/Chinese contrasts for the platelet criterion: explicit symptom-based uncertainty plus warning; uncertainty only about the clumped sample plus warning; warning alone; affirmative false reassurance. Keep the implicit-equivalence example unadjudicated. Do not modify the current labels or retrofit the original answer's status.
2. Make the distinction between an already-counted criterion/error and a genuinely additional observation explicit in a separate prospective instruction/fixture draft. Preserve both old observations; no added numeric penalty or keyword-based clinical adjudication.
3. Check that selected evidence covers each positive function and qualification actually claimed in the rationale. A relevant fragment is not proof of an entire rationale. Do not silently widen old citations or require longer answers simply to make them easier to quote.

After the offline version and acceptance rules are fixed, decide the smallest justified confirmation scope and seek new approval. The previously planned broader bilingual/multi-family run stays conditional; this failed gate does not trigger automatic repeat calls. Development calibration is **not finished**, and an exact remaining batch count would be misleading until these boundaries are resolved. Independent clinical ratings and held-out evaluation are still separate later gates.

The desired lower/mid/premium bands of **60–70 / around 80 / around 90** remain difficulty diagnostics, never a target curve to force. Public inventory is unchanged at **135 draft families / 270 variants**, 365 families short of 500; approved calibration/Gold remains **0/0**. This diagnostic added no cases. Source-backed authoring can continue independently; Xi'an and purchased source records stay local.

## Audit and verification

The read-only [S67 auditor](../scripts/audit_compact_s67.py) first replays S66's raw captures, then reports criterion changes, observation changes and reference changes separately. It requires one hash-bound local review row per accepted evidence/null entry; missing, duplicate, stale or falsely independent review records are rejected. It never contacts a provider or changes scores. The source journal hash is `9f7c7ad7808e7c05665675840b5ff454e5525e8993d7bb3ba8560b2d4cc97f49`; its protocol is the unchanged S66 freeze. Raw answers, reasoning, keys and authorization evidence are not exported.

Verification: **45 focused offline tests passed in 41.855 seconds**, covering the ten new audit tests and all 35 frozen-runner tests. The public report reproduces exactly, the S66 freeze and original S62 journal are unchanged, and all 1,495 checked local Markdown links resolve. The 19 public changed files contain no detected credential patterns or private-data file paths; keys, consent and raw replies remain ignored. The earlier 1,256-test full-suite result belongs to S66; the full suite was not rerun for this read-only addition.
